EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma

This study is for patients that have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or T/NK-lymphoproliferative disease which has come back or has not gone away after treatment, including the best treatment the investigators know for these diseases. Some patients with Lymphoma or T/NK-lymphoproliferative disease show signs of virus that is sometimes called Epstein Barr virus (EBV) that causes mononucleosis or glandular fever ("mono") before or at the time of their diagnosis. EBV is found in the cancer cells of up to half the patients with Hodgkin's and non-Hodgkin Lympho

Trial Details

NCT ID
NCT04664179
Phase
PHASE1
Sponsor
Baylor College of Medicine
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Dose Level 1A: 2 x 10^7 cells/m2
  • Dose Level 2A: 6 x 10^7 cells/m2
  • Dose Level 2B: 6 x 10^7 cells/m2
  • Dose Level 3B: 2 x 10^8 cells/m2
  • Dose Level 3A: 2 x 10^8 cells/m2
  • Dose Level 1B: 2 x 10^7 cells/m2
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327
  • Houston, Texas, United States|29.76328,-95.36327
  • Houston, Texas, United States|29.76328,-95.36327
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Any patient, regardless of age or sex, with EBV-positive Hodgkin's or non Hodgkin's Lymphoma, (regardless of the histological subtype) or EBV (asso…
  • EBV positive tumor (can be pending)
  • Weighs at least 10 kg
  • Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given a copy of informed consent.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →